PEDIATRIX MEDICAL GROUP INC (MD)
US58502B1061 - Common Stock
Overall MD gets a fundamental rating of 3 out of 10. We evaluated MD against 117 industry peers in the Health Care Providers & Services industry. MD has a bad profitability rating. Also its financial health evaluation is rather negative. MD has a bad growth rate and is valued cheaply.
1. Profitability
1.1 Basic Checks
In the past year MD was profitable.
MD had a positive operating cash flow in the past year.
In multiple years MD reported negative net income over the last 5 years.
In the past 5 years MD always reported a positive cash flow from operatings.
1.2 Ratios
MD has a Return On Assets (-2.72%) which is in line with its industry peers.
MD has a Return On Equity (-7.11%) which is in line with its industry peers.
Looking at the Return On Invested Capital, with a value of 6.63%, MD is in the better half of the industry, outperforming 72.41% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for MD is in line with the industry average of 8.60%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.72% | ||
| ROE | -7.11% | ||
| ROIC | 6.63% |
ROA(3y)1.64%
ROA(5y)-11%
ROE(3y)4.98%
ROE(5y)-38.31%
ROIC(3y)7.31%
ROIC(5y)6.29%
1.3 Margins
Looking at the Operating Margin, with a value of 7.91%, MD is in the better half of the industry, outperforming 79.31% of the companies in the same industry.
MD's Operating Margin has declined in the last couple of years.
The Profit Margin and Gross Margin are not available for MD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.91% | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3Y-7.23%
OM growth 5Y-11.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MD is destroying value.
Compared to 1 year ago, MD has more shares outstanding
Compared to 5 years ago, MD has less shares outstanding
MD has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.43, we must say that MD is in the distress zone and has some risk of bankruptcy.
MD has a Altman-Z score (1.43) which is in line with its industry peers.
MD has a debt to FCF ratio of 6.09. This is a slightly negative value and a sign of low solvency as MD would need 6.09 years to pay back of all of its debts.
MD has a better Debt to FCF ratio (6.09) than 71.55% of its industry peers.
A Debt/Equity ratio of 0.73 indicates that MD is somewhat dependend on debt financing.
The Debt to Equity ratio of MD (0.73) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.73 | ||
| Debt/FCF | 6.09 | ||
| Altman-Z | 1.43 |
ROIC/WACC0.87
WACC7.59%
2.3 Liquidity
A Current Ratio of 1.24 indicates that MD should not have too much problems paying its short term obligations.
MD has a Current ratio of 1.24. This is comparable to the rest of the industry: MD outperforms 43.97% of its industry peers.
A Quick Ratio of 1.24 indicates that MD should not have too much problems paying its short term obligations.
MD has a Quick ratio of 1.24. This is comparable to the rest of the industry: MD outperforms 47.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.24 | ||
| Quick Ratio | 1.24 |
3. Growth
3.1 Past
The earnings per share for MD have decreased strongly by -24.55% in the last year.
Measured over the past years, MD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -19.89% on average per year.
Looking at the last year, MD shows a small growth in Revenue. The Revenue has grown by 1.15% in the last year.
MD shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.97% yearly.
EPS 1Y (TTM)-24.55%
EPS 3Y0%
EPS 5Y-19.89%
EPS growth Q2Q-31.91%
Revenue 1Y (TTM)1.15%
Revenue growth 3Y4.78%
Revenue growth 5Y2.97%
Revenue growth Q2Q-3.39%
3.2 Future
MD is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.62% yearly.
MD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.04% yearly.
EPS Next Y1.67%
EPS Next 2Y2.59%
EPS Next 3Y1.72%
EPS Next 5Y-2.62%
Revenue Next Year0.82%
Revenue Next 2Y2.09%
Revenue Next 3Y2.82%
Revenue Next 5Y4.04%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 7.40, the valuation of MD can be described as very cheap.
MD's Price/Earnings ratio is rather cheap when compared to the industry. MD is cheaper than 96.55% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 28.28. MD is valued rather cheaply when compared to this.
With a Price/Forward Earnings ratio of 7.28, the valuation of MD can be described as very cheap.
Based on the Price/Forward Earnings ratio, MD is valued cheaply inside the industry as 96.55% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.88, MD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.4 | ||
| Fwd PE | 7.28 |
4.2 Price Multiples
MD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MD is cheaper than 95.69% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, MD is valued cheaper than 92.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.54 | ||
| EV/EBITDA | 5.76 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)4.43
PEG (5Y)N/A
EPS Next 2Y2.59%
EPS Next 3Y1.72%
5. Dividend
5.1 Amount
No dividends for MD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PEDIATRIX MEDICAL GROUP INC
NYSE:MD (5/3/2024, 7:05:10 PM)
After market: 9.79 +0.46 (+4.93%)9.33
+0.21 (+2.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap784.00M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.4 | ||
| Fwd PE | 7.28 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)4.43
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.72% | ||
| ROE | -7.11% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 7.91% | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.9
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.73 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.24 | ||
| Quick Ratio | 1.24 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-24.55%
EPS 3Y0%
EPS 5Y
EPS growth Q2Q
EPS Next Y1.67%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)1.15%
Revenue growth 3Y4.78%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y